A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia
NCT03271541 2016-004799-23 BP39642
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
This proof-of-mechanism study is being performed to investigate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of multiple oral doses of bitopertin in adults with NTD beta-thalassemia. This study consists of two parts: Part 1 - The main study - 16 weeks in total: Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose. Part 2 - Open Label Extension (OLE) - up to an additional 12 months. Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed. Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period.
A Phase II, Single Arm, Multicenter, Proof-of-Mechanism Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent Βeta-Thalassemia
- Confirmed diagnosis of beta-thalassemia
- Clinically defined non-transfusion-dependent anemia (Part 1 only), defined as Hb concentrations >7.5 grams per deciliter (g/dL) and <9.5 g/dL, less than or equal to 4 transfusions of red blood cell units within 1 year prior to study enrollment, and no transfusion within 12 weeks prior to study enrollment
- Completion of 16 weeks of treatment with bitopertin in Part 1 of this study with more than 80% compliance from expected use of study medication (based on patient diary and study drug accountability; Part 2 only)
- A favorable benefit-risk ratio from treatment with bitopertin as assessed by the Investigator (Part 2 only)
- Any history of gene therapy
- History of hemolytic anemia except for beta-thalassemia
- Severe symptomatic splenomegaly and/or hepatomegaly with hypersplenism (Part 1 only)
- Any use of an erythropoiesis-stimulating agent within 24 weeks prior to enrollment.
- Initiation of iron chelation therapy or hydroxyurea within 24 weeks prior to enrollment (Part 1 only)
- Depression, treatment with anti-depressants, or other psychiatric illnesses and/or drug abuse
- Clinically significant/uncontrolled comorbid disease
- Pregnant or breastfeeding females
- Use of cytochrome P450 (CYP) 3A4 inhibitors within 2 weeks or CYP3A4 inducers within 4 weeks prior to study drug
- Active hepatitis B or C or known positive human immunodeficiency virus (HIV) test result
- Diagnosis of cancer within previous 5 years unless treatment has resulted in complete freedom from disease for at least 2 years
- Any major illness within 1 month or febrile illness within 1 week prior to study drug
- Pulmonary hypertension requiring oxygen therapy (Part 1 only)
For the latest version of this information please go to www.forpatients.roche.com